Management of the australianclinicaltrials.gov.au website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal.

Clinical Trial Details

Treatment of glucocorticoid-induced protein wasting

Print record Print record
Trial Information

Broad Health Condition Inflammatory and Immune System

Specific Health ConditionRheumatoid arthritis

Trial FocusTreatment

Recruitment statusRecruiting

Anticipated date of first participant enrolment1/07/2004

Anticipated date of last participant enrolment1/07/2004

Phase of TrialPhase 2 / Phase 3

Has the study received ethics approval?Further information iconApproved

Trial summary

The primary purpose is to determine whether growth hormone and androgens alter protein metabolism in a way that will reduce protein loss in long-term glucocorticoid users. If so they may be a potential therapy to reduce the skin thinning and muscle weakness that occurs during longterm glucocorticoid use.
Eligibility

Key inclusion criteria

Receiving prednisone for > 6 months for polymyalgia rheumatica or inflammatory arthritis.

GenderBoth males and females

Can Healthy volunteers participate?No

Key exclusion criteria

Diabetes mellitus, cancer, liver or kidney failure.
Contact details and further information

Sponsor Primary Sponsor Type: Hospital
Primary Sponsor Name: St Vincent's Hospital
Primary Sponsor Country: Australia

Trial IDACTRN12605000642684

Contact person for information and recruitment
Professor Ken Ho
Pituitary Research Unit Garvan Institute of Medical Research 384 Victoria St Darlinghurst NSW 2010
+61 2 92958482
+61 2 92958481
Further information iconk.ho@garvan.org.au
Australia